Kim M. Hirshfield

Merck & Co., Inc., Rahway, NJ, USA (United States)

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Targetable Alterations in Invasive Pleomorphic Lobular Carcinoma of the Breast”.

Targetable Alterations in Invasive Pleomorphic Lobular Carcinoma of the Breast

Research Square(2020)10.21203/rs.3.rs-109612/v1

N/A

0DataRank · unranked

0 citations

Sonali Joshi, Kim M. Hirshfield, Nicola Barnard, Shridar Ganesan, Gregory Riedlinger

Targetable alterations in invasive pleomorphic lobular carcinoma of the breast

Breast Cancer Research(2021)10.1186/s13058-020-01385-5

N/A

0DataRank · unranked

21 citations

Sonali Joshi, Kim M. Hirshfield, Nicola Barnard, Shridar Ganesan, Gregory Riedlinger

The role of chromodomain helicase DNA binding protein 1 (CHD1) in promoting an invasive prostate cancer phenotype

Therapeutic Advances in Urology(2021)10.1177/17562872211022462

N/A

0DataRank · unranked

7 citations

Daniel Medina, Whitney Petrosky, Sonia Dolfi, Irina V. Tereshchenko, Kelly Walton +6 more

A functionally significant SNP in TP53 and breast cancer risk in African-American women

UNC Libraries(2024)10.17615/z533-aj20

N/A

0DataRank · unranked

0 citations

Qingyi Liu, S.C. Dolfi, Kim M. Hirshfield, Chung-Hung Hong, Michael F. Press +28 more